Table of Content


COMPANY EXECUTIVE SUMMARY 1
Table of Contents 2
Tables 6
Charts 7
Astellas Pharma Inc.-Key Company Facts 8
Astellas Pharma Inc.- Company Description 9
Astellas Pharma Inc.- Top Executives 10
Astellas Pharma Inc.- Head Office & Locations 12
Head Office - Country 12
Astellas Pharma Inc.- Productsand Services 13
Products 13
Services 14
Astellas Pharma Inc.- Corporate Strategy 15
Astellas Pharma Inc.- Business Description 18
Immunology Segment 19
Urology Segment 20
Oncology Segment 20
Astellas Pharma Inc.- ESG Spotlight 21
Environment 22
Social 22
Corporate Governance 22
Astellas Pharma Inc.- SWOT Analysis 24
Overview 24
Strengths 26
Weaknesses 30
Opportunities 31
Threats 33
Astellas Pharma Inc.- PESTLE Analysis 34
Overview 34
Political Factors 36
Economic Factors 38
Social Factors 39
Technological Factors 41
Legal Factors 43
Environmental Factors 44
Astellas Pharma Inc.- Financial Deep Dive 45
Share Price Trend - Nov-2023 to Nov-2024 (Average Share Closing Price) 45
Profit and Loss Statement 47
Summary of Profit and Loss Statement 47
Balance Sheet 49
Summary of Balance Sheet 49
Cash Flow Statement 51
Summary of Cash Flow Statement 51
Key Financial Ratio Analysis 53
Astellas Pharma Inc.- Ratio Charts 54
Activity Ratio Charts 54
Growth Ratios Charts 55
Leverage Ratio Charts 56
Liquidity Ratio Charts 57
Profitability Ratio Charts 58
Competing Players 59
Snapshot of Competing Players 60
Johnson & Johnson 60
Key Company Facts 60
Company Description 60
Novartis AG 61
Key Company Facts 61
Company Description 61
Pfizer Inc. 62
Key Company Facts 62
Company Description 62
Merck & Co., Inc. 63
Key Company Facts 63
Company Description 63
GlaxoSmithKline Pharmaceuticals Ltd 64
Key Company Facts 64
Company Description 64
Astellas Pharma Inc. - In the News 65
28-Oct-2024 -Astellas Provides Update on Marketing Authorization Application for Avacincaptad Pegol (ACP) in the European Union 65
25-Oct-2024 -Every Day of Vision Loss Is One Too Many: Addressing the Impact of Eye Diseases 66
21-Oct-2024 -stellas’ VYLOYTM (zolbetuximab-clzb) Approved by U.S. FDA for Treatment of Advanced Gastric and GEJ Cancer 66
18-Oct-2024 -Silence, Stigma, and Misunderstanding: Our Mission to Break Down Barriers in Menopause 68
10-Oct-2024 -Astellas to Present VEOZATM (fezolinetant) Data at IMS World Congress on Menopause 70
08-Oct-2024 -Astellas and AviadoBio Announce Exclusive Option and License Agreement for Gene Therapy AVB-101 Targeting Frontotemporal Dementia and Other Indications 71

30-Sep-2024 -Notice Regarding Foreign Exchange Loss 72
24-Sep-2024 -Japan’s Ministry of Health, Labour and Welfare Approves PADCEVTM (enfortumab vedotin) with KEYTRUDA? (pembrolizumab) for First-Line Treatment of Radically Unresectable Urothelial Carcinoma 72

30-May-2024 -U.S. FDA ACKNOWLEDGES ASTELLAS’ RESUBMISSION OF BIOLOGICS LICENSE APPLICATION FOR ZOLBETUXIMAB AND SETS NEW ACTION DATE 74
21-May-2024 -Astellas Announces a Collaboration with YASKAWA to Create an Innovative Cell Therapy Ecosystem through the Integration of Pharmaceutical and Robotics Technologies 76
19-May-2024 -Patient Centricity and AI: Navigating the Promise and Pitfalls 77
15-May-2024 -Notice Regarding Continuation of the Performance-linked Stock Compensation Scheme 80
Appendix 81
Definitions 81
SWOT Analysis 81
PESTLE Analysis 81
Value Chain Analysis 81
ESG Spotlight 81
Financial Deep Dive 81
Financial Ratios- 82
Activity Ratios 82
Growth Ratios 83
Leverage Ratios 84
Liquidity Ratios 85
Market Ratios 86
Profitability Ratios 86
Research Methodology 87
Disclaimer 88
Contact Us 88



List of Figures

Charts

Figure 1: Astellas Pharma Inc.- SWOT Analysis 25
Figure 2: Astellas Pharma Inc.-PESTLE Analysis 35
Figure 3: Astellas Pharma Inc.-Average Share Price Trend - Nov-2023to Nov-2024 46
Figure 4: Astellas Pharma Inc.- Profit and Loss Statement -2021-2024 48
Figure 5: Astellas Pharma Inc.- Balance Sheet-2021-2024 50
Figure 6: Astellas Pharma Inc.- Cash Flow Statement 2021-2024 52
Figure 7: Astellas Pharma Inc.- Activity Ratio Charts 54
Figure 8: Astellas Pharma Inc.- Growth Ratio Charts (Value %) 55
Figure 9: Astellas Pharma Inc.- Leverage Ratio Charts 56
Figure 10: Astellas Pharma Inc.- Liquidity Ratio Charts 57
Figure 11: Astellas Pharma Inc.- Profitability Ratio Charts (Value %) 58

List of Tables

Tables
Table 1: Astellas Pharma Inc. - Company Facts
Table 2: Astellas Pharma Inc. - Digital Presence
Table 3: Astellas Pharma Inc.- Top Executives
Table 4: Astellas Pharma Inc.- Products
Table 5: Astellas Pharma Inc.-Services
Table 6: Astellas Pharma Inc. - Share Price Trend - Nov-2023to Nov-2024
Table 7: Astellas Pharma Inc. - Ratio Analysis -2021-2024
Table 8: Astellas Pharma Inc. - Competing Players
Table 9: Competing Players - Johnson & Johnson - Key Company Facts
Table 10: Competing Players - Novartis AG - Key Company Facts
Table 11: Competing Players - Pfizer Inc. - Key Company Facts
Table 12: Competing Players - Merck & Co., Inc. - Key Company Facts
Table 13: Competing Players - GlaxoSmithKline Pharmaceuticals Ltd - Key Company Facts